ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,921, issued on Nov. 25, was assigned to Oricell Therapeutics Co. Ltd. (Shanghai).
"Anti-PD-L1 antibody and use thereof" was invented by Bohua Li (Shanghai), Huajing Wang (Shanghai) and Xiaowen He (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the...